Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aronow W. S., Allen W. H., De Cristofaro D. Response of patients and physicians to mass screening for coronary risk factors. Circulation. 1975 Oct;52(4):586–588. doi: 10.1161/01.cir.52.4.586. [DOI] [PubMed] [Google Scholar]
- Frohlich E. D., Messerli F. H., Dunn F. G., Oigman W., Ventura H. O., Sundgaard-Riise K. Greater renal vascular involvement in the black patient with essential hypertension. A comparison of systemic and renal hemodynamics in black and white patients. Miner Electrolyte Metab. 1984;10(3):173–177. [PubMed] [Google Scholar]
- Harron D. W., Jady K., Riddell J. G., Shanks R. G. Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol. 1982 Mar-Apr;4(2):213–220. doi: 10.1097/00005344-198203000-00008. [DOI] [PubMed] [Google Scholar]
- Levy S. B., Talner L. B., Coel M. N., Holle R., Stone R. A. Renal vasculature in essential hypertension: racial differences. Ann Intern Med. 1978 Jan;88(1):12–16. doi: 10.7326/0003-4819-88-1-12. [DOI] [PubMed] [Google Scholar]
- McGonigle R. J., Williams L., Murphy M. J., Parsons V. Labetalol and lipids. Lancet. 1981 Jan 17;1(8212):163–163. doi: 10.1016/s0140-6736(81)90759-5. [DOI] [PubMed] [Google Scholar]